Add Row
Add Element
The MedSpa Journal Logo
update
The MedSpa Journal
The MedSpa Journal Logo
update
Add Element
  • Home
  • Categories
    • Trends
    • Marketing
    • Tech
    • Education
    • Regulations
    • Resources
    • Extra News
December 13.2025
4 Minutes Read

A New Era in Sun Care: FDA Reviews Bemotrizinol for Sunscreens

Close-up of bemotrizinol sunscreen applied to shoulder, natural lighting.

Understanding Bemotrizinol: A Game Changer for Sunscreens

On December 11, 2025, the FDA made an announcement that could significantly change how Americans approach sun protection. The agency has proposed allowing bemotrizinol, a potent UV filter already widely used internationally, to be included in the list of active ingredients permitted in U.S. sunscreens. This groundbreaking development aims to expand consumer options while ensuring effective protection against harmful ultraviolet (UV) rays.

Bemotrizinol, commonly referred to as BEMT, offers comprehensive protection against both UVA and UVB rays. Current protections in the U.S. have remained limited, consisting of only 16 active ingredients, compared to the 30+ available in countries like Europe. The FDA's proposal is a much-needed step towards modernizing sunscreen regulations and making better products available to consumers.

Key Points Solutions
FDA reviewing the proposal for bemotrizinol inclusion. Complete participation in the public comment process.
BEMT offers low absorption and minimal skin irritation. Educate patients on the safety and efficacy of BEMT.
Only the third sunscreen ingredient approved for children 6 months and older. Advocate for sunscreen safety for all ages in your practice.
Potential for better texture and experience in sunscreen formulation. Engage in discussions about product development with manufacturers.

Why Bemotrizinol Matters in the Sunscreen Market

The introduction of bemotrizinol has significant implications for the United States, where sunscreen has historically lagged behind global innovations. "With chemical sunscreens, a substantial gap exists in formulation due to a limited number of approved filters,” says cosmetic chemist Victoria Fu. BEMT is among the first proposals for a new chemical sunscreen ingredient in 26 years, following the last addition in 1999.

According to Dr. Michelle Henry, a dermatologist, BEMT's photostable characteristics mean it can provide superior UV protection compared to existing options. Its stability under sunlight is particularly critical for ensuring efficacy and consumer safety.

Key Points Solutions
BEMT improves consumer sunscreen experience. Promote lightweight, non-greasy formulations to attract users.
It enhances broad-spectrum protection. Educate clients on the importance of broad-spectrum sunscreens.
Supports skin cancer prevention through better formulation. Encourage regular sunscreen use among your clients.
Leverages global standards for UV protection. Stay updated with international UV protection trends.

The Implementation of Bemotrizinol in Formulations

Should the FDA’s proposal come to fruition, bemotrizinol is expected to open up new avenues for sunscreen formulations. The increased efficiency of BEMT allows cosmetic chemists to achieve targeted SPF levels with lower concentrations, potentially improving the sensory experience of sunscreen products.

However, industry players must remain diligent in ensuring that sunscreens formulated with BEMT comply with necessary safety protocols and do not compromise on UV protection. Many manufacturers already possess BEMT formulas for international markets, streamlining the transition should approval be granted.

Sunscreen Application
Applying sunscreen that could soon include bemotrizinol.
Sun Exposure
Understanding UV exposure is crucial for effective sun protection.
Key Points Solutions
Focus on the effective use of BEMT in formulas. Inquire about product options that include BEMT.
Potential market differentiation with BEMT products. Create targeted marketing campaigns highlighting new ingredient.
Addressing public concerns over ingredient safety. Host information sessions about ingredient safety and efficacy.
Collaboration with manufacturers will drive innovation. Force discussions with suppliers about new product offerings.

Conclusion: The Future of Sunscreens with BEMT

In summary, the FDA’s proposal to include bemotrizinol could significantly alter the sunscreen landscape in the United States, providing more effective, user-friendly options in sun protection. As medical spa owners, staying informed and engaged with this development is crucial to enhance your product offerings and educate your clients.

To navigate this change effectively, consider exploring these actionable steps:

  • Engage with your suppliers regarding BEMT product availability.
  • Educate clients on the importance of sunscreen reapplication.
  • Participate in the public comment period to voice support for bemotrizinol.
  • Train staff on the specifications and benefits of newer sunscreen formulations.

Frequently Asked Questions

  • What is bemotrizinol? Bemotrizinol is a chemical UV filter that protects against both UVA and UVB rays and is proposed for use in U.S. sunscreens.
  • Why is this proposal significant? It will expand available sunscreen options and enhance consumer protection against UV damage.
  • When will BEMT be available in the U.S.? While the exact timeline is uncertain, products could begin marketing as early as late 2026, pending FDA approval.
Key Takeaways Solutions
BEMT proposal could revolutionize sun protection options. Stay educated on regulatory changes affecting sunscreen.
Greater access to safe ingredients for children. Promote sunscreen awareness for family use.
Importance of initiating public discussions. Encourage your community to partake in comment periods.
Emphasis on ingredient transparency and safety. Provide detailed consultations about sunscreen safety.
Extra News

Write A Comment

*
*
Related Posts All Posts

Breakthrough for Women's Health: Addyi Now Approved for Postmenopausal HSDD

Update The FDA Breakthrough: Addyi for Postmenopausal WomenThe recent approval of Addyi (flibanserin) by the FDA is a significant milestone in women's health, particularly for postmenopausal women battling Hypoactive Sexual Desire Disorder (HSDD). This condition affects an astonishing 40% to 55% of women post-menopause, often exacerbated by hormonal fluctuations that result in decreased libido and emotional challenges. For too long, these women have faced a void of treatment options, but with the approval of Addyi, there is now hope.Understanding HSDD and Its ImplicationsHSDD is defined by a persistent lack of sexual desire that causes distress in one’s personal or interpersonal relationships. It can also be rooted in other health issues, including anxiety and depression, which disproportionately affect women, especially during and after the menopausal transition. The approval of Addyi marks a critical acknowledgment of the need for adequate sexual health support throughout a woman's life cycle. Rachel Rubin, MD, a sexual medicine expert, highlights the significance of this acknowledgment: "It's a critical recognition that their pleasure, their wellbeing, and their quality of life matter." Currently, many treatment options exist primarily for men, but the landscape is changing. With Addyi, women have access to a therapy that is not hormone-based, providing a new approach tailored to address the unique challenges of sexual desire in postmenopausal patients.How Addyi Works: The Mechanism Behind the MedicationAddyi operates by modifying brain chemistry rather than replacing hormones. This drug stabilizes neurotransmitters like dopamine and norepinephrine, which are crucial in promoting sexual desire. While other treatments focus on estrogen replacement, Addyi offers a non-hormonal alternative, which is particularly advantageous for women who either cannot or do not wish to engage in hormone therapy due to side effects or health concerns. The expansion of Addyi's application to include postmenopausal women underscores a growing understanding within the medical community about women's sexual health needs.The Journey to Approval: Overcoming Stigmas in Women’s HealthThe pathway to Addyi's approval has been fraught with challenges, including societal stigmas surrounding women's sexual health. Cindy Eckert, the Founder and CEO of Sprout Pharmaceuticals, referred to the FDA's decision as a breakthrough and a reflection of the dedication to reshaping women’s sexual health discourse. The journey has seen advocates for women’s health pushing for more research and visibility for women's sexual dysfunction conditions, helping pave the way for this long-overdue acknowledgment.Making Informed Choices: Next Steps for Patients and ProvidersFor medical spa owners and practitioners, staying informed about the implications of Addyi's approval is paramount. Patients will benefit from comprehensive consultations regarding the pros and cons of using Addyi. Providers should aim to facilitate open discussions that explore the multi-faceted nature of libido and sexual health. Consideration of the various underlying issues a patient may present with is essential, as libido can be influenced by psychological factors, previous medical history, and relational dynamics.As a medical spa owner, understanding the potential for Addyi to enhance the quality of life for women in your practice can open up new dialogues and care opportunities. Encourage patients to share their experiences, as these conversations can lead to more robust understandings of sexual health at any stage of life.

Is Your Medical Spa Ready for the WHO's New GLP-1 Obesity Guidelines?

Update The WHO Tackles Obesity: A New Guideline UnveiledOn December 1, 2025, the World Health Organization (WHO) made a groundbreaking announcement by releasing its first-ever guidance on GLP-1 therapies for treating obesity, a decision that comes amidst an escalating global health crisis. With over a billion people affected by obesity worldwide, and projections suggesting the number could double by 2030, this comprehensive guideline aims to integrate GLP-1 medications as part of a broader approach to managing this complex condition.The Role of GLP-1 Therapies in Obesity ManagementGLP-1 (Glucagon-Like Peptide-1) therapies, historically praised for their effectiveness in weight management, were highlighted in the WHO's guidelines for their potential to revolutionize the treatment landscape of obesity. Depending on conditions set forth by the WHO, these medications, which include liraglutide and semaglutide, are positioned as a long-term treatment option for adults suffering from this chronic disease, although pregnant women are advised against their use due to limited safety data.Integration of Lifestyle Changes: The Key to SuccessOne significant aspect of the WHO's guidelines emphasizes the necessity of combining GLP-1 therapies with lifestyle interventions. The recommendation suggests integrating healthy diets and regular physical activity into treatment plans, underscoring the reality that medication alone cannot address the obesity epidemic. This multifaceted approach advocates for a supportive environment that encompasses behavioral counseling and continued engagement with healthcare professionals for optimal results.Raising Concerns: Health Inequalities and System PreparednessWhile the promise of GLP-1 therapies is evident, the WHO has issued caution regarding the potential exacerbation of health inequalities. Accessible and affordable healthcare solutions must be a priority, as current systems are ill-equipped to handle the anticipated rise in demand. The organization urged governments and health providers to work collaboratively to create equitable access to these treatments, particularly for underserved populations, and to prevent the proliferation of counterfeit medications.The Call for a New Healthcare EcosystemThe WHO advocates for a shift towards building a global 'obesity ecosystem' that emphasizes early diagnosis and treatment of obesity. This ecosystem should support individuals of all backgrounds, ensuring that advancements in medical therapies do not deepen existing disparities. The acknowledgment of the economic burden associated with obesity, forecasted to reach $3 trillion annually by 2030, highlights the urgency of addressing this public health crisis holistically.What's Next? Future Implications of the New GuidelinesAs the WHO looks to present new evidence and adapt the guidelines over time, the impact of these recommendations will evolve. Innovations such as TrumpRX’s anticipated affordable GLP-1 offerings in 2026 may change the landscape of obesity treatment accessibility. Medical spa owners and healthcare practitioners must stay informed of these developments to align their services and practices with the shifting paradigm towards more integrated, patient-centered care.The Broader Implications for Medical ProfessionalsFor medical spa owners and practitioners, understanding these new guidelines is crucial not only for compliance but also for ensuring that patients receive the most efficacious and equitable care. Engaging in conversations around the ethical implications, access, and quality of treatment will not only realign practice standards but also enhance patient outcomes in a field that demands ongoing learning and adaptation.In conclusion, the WHO's guidelines on GLP-1 therapies signify a pivotal moment in the journey towards an effective, equitable response to obesity. As medical spa owners, understanding and implementing these guidelines in conjunction with comprehensive treatment approaches could improve patient health outcomes and enhance the credibility of the services offered. By actively participating in this evolving landscape, practitioners can respond proactively to the growing demand for obesity management solutions and contribute positively to global health efforts.

FDA's NMN Reinstatement Opens New Doors for Medical Spas in NAD+ Therapy

Update FDA's About-Face: NMN Returns to Supplement Market The FDA's recent reinstatement of Nicotinamide Mononucleotide (NMN) as a lawful dietary supplement marks a significant shift in regulatory stance, opening doors for medical spa owners to explore new avenues in wellness therapies. Initially, NMN was removed from the market in 2022 after being placed under the drug preclusion provision of the Dietary Supplement Health and Education Act (DSHEA). However, due to increased advocacy from industry leaders and public petitioning, the FDA has reversed its decision, allowing NMN back into the dietary supplement category. The Role of NMN in NAD+ Therapy NMN is a precursor to nicotinamide adenine dinucleotide (NAD+), a vital coenzyme involved in energy metabolism and cellular health. The renewed legality of NMN suggests a harmonization with medical-grade NAD+ therapies commonly offered at medspas. Medical spa owners can now pair NMN supplements with NAD+ infusions, potentially amplifying the benefits of their regenerative health programs. This trend could be of significant interest to spa owners seeking innovative treatment combinations to attract clients. Consumer Health and Quality Concerns While the news is promising, it brings up concerns regarding quality and safety. Past analyses indicated that many NMN products available online failed to deliver on their label claims, with only a minority containing detectable levels of the compound. As the market for NMN expands, ensuring that products meet rigorous quality standards will be crucial for safeguarding consumer trust. The Competitive Landscape: NMN vs. NR In the evolving supplement landscape, NMN faces competition from another NAD+ precursor—Nicotinamide Riboside (NR). Recent research suggests NR could be more efficient than NMN, boosting NAD+ levels more effectively due to its different metabolic pathway. For medical spas, this raises questions about product offerings and marketing strategies. Spa owners may need to highlight not just the availability of NMN but also educate clients about the comparative benefits of various NAD+ precursors. Implications for Medspas and Future Trends The reinstatement of NMN comes amidst a broader trend toward the integration of nutritional supplements into aesthetic and wellness treatments. As patients show greater interest in supplements that support healthy aging and metabolic function, medspas can position themselves at the forefront of this trend. Offering comprehensive wellness plans that include NMN and GLP-1 medications could differentiate spas in a competitive market. Actionable Steps for Medical Spa Owners For spa owners aiming to leverage the renewed NMN status, consider the following steps: Education: Inform staff about NMN, its benefits, and how it complements NAD+ therapies. Quality Assurance: Source NMN products from reputable suppliers to ensure compliance and quality. Client Engagement: Create marketing materials that educate clients about the importance of NAD+ in wellness. Monitor Regulatory Updates: Stay informed on FDA guidelines and potential changes to supplement regulations. These steps will not only enhance service offerings but also build trust with clients who seek quality in their health products. The reinstatement of NMN represents a noteworthy development for the health and wellness industry. As the landscape continues to evolve, medspa owners have an opportunity to align their services with emerging trends, ensuring they remain competitive in this dynamic market. Engage with your clientele, educate them on wellness innovations, and embrace the potential of NMN as part of a holistic approach to health.

Terms of Service

Privacy Policy

Core Modal Title

Sorry, no results found

You Might Find These Articles Interesting

T
Please Check Your Email
We Will Be Following Up Shortly
*
*
*